{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T06:27:43Z","timestamp":1786429663566,"version":"build-2736575974"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Intratumoral heterogeneity (ITH) is associated with poor prognosis in various solid tumors. However, its use as a predictive biomarker for immunotherapy in advanced non-small cell lung cancer (NSCLC) is still lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used Maftools to analyze somatic variants of NSCLC from independent cohorts (POPLAR, OAK, Hellmann2018) including 504 patients with advanced NSCLC. Additionally, 121 patients (in-house cohort) with NSCLC who received radical treatment and underwent 733-panel NGS testing of surgical samples were included. We used Shannon entropy to measure ITH, analyzed correlation with immunogenic markers, and explored ITH\u2019s prognostic effect on immunotherapy and its role in predicting postoperative recurrence risk. Using the TCGA cohort, we compared genetic characteristics between low ITH (ITH-L) and high ITH (ITH-H) groups, assessed mutational profiles, and evaluated associations between ITH scores and immune cell populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the Hellmann2018 cohort, ITH-L correlated with higher durable clinical benefit (DCB) rate, objective response rate (ORR), and median progression-free survival (mPFS), highlighting ITH-L as a potential positive predictor for ICI therapy. Combining ITH with TMB revealed that ITH-L\/TMB-H patients had significantly better DCB, ORR, and mPFS, supporting the potential predictive value of ITH when evaluated together with TMB. Validation in POPLAR\/OAK cohorts supported the association of ITH, alone or combined with TMB, with immunotherapy outcomes. ITH-L patients exhibited higher DCB, ORR, longer mPFS, and median overall survival (mOS). Combining ITH and circulating tumor DNA validated these findings. In early-stage surgical NSCLC patients, ITH-L was associated with significantly higher median recurrence-free survival (mRFS). Mechanistically, the ITH-L group showed elevated TMB, neoantigen (SNV), and subclonal genome fraction, alongside reduced HRD scores and CNV burden. Mutational analysis identified XIRP2 as the most frequently altered gene, enriched in the ITH-L group, while SHOX2 was the only gene with higher frequency in the ITH-H group. Immune infiltration analysis revealed significant differences in M1 macrophages, activated memory CD4+ T cells, and naive CD4+ T cells between groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ITH may serve as a potential biomarker associated with immunotherapy outcomes in advanced NSCLC and postoperative recurrence risk in early-stage surgical patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1852284","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T05:34:48Z","timestamp":1786426488000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Intratumoral heterogeneity as a potential biomarker for immunotherapy response and postoperative recurrence in NSCLC"],"prefix":"10.3389","volume":"17","author":[{"given":"Yuhang","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yucheng","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuju","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yating","family":"Zheng","sequence":"additional","affiliation":[{"name":"Medical Department, 3D Medicines Inc.","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haofei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1186\/s12964-024-01639-1","article-title":"Integrin \u03b1V\u03b21-activated PYK2 promotes the progression of non-small-cell lung cancer via the STAT3-VGF axis","volume":"22","author":"Wu","year":"2024","journal-title":"Cell Commun Signal"},{"key":"B2","doi-asserted-by":"publisher","first-page":"a037895","DOI":"10.1101\/cshperspect.a037895","article-title":"Tumor immunology and immunotherapy of non-small-cell lung cancer","volume":"12","author":"Cascone","year":"2022","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.10.001","article-title":"The challenges of tumor mutational burden as an immunotherapy biomarker","volume":"39","author":"Jardim","year":"2021","journal-title":"Cancer Cell"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0219682","article-title":"Assessment of intratumoral heterogeneity with mutations and gene expression profiles","volume":"14","author":"Sung","year":"2019","journal-title":"PloS One"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30437","article-title":"Multiregion sequencing reveals the intratumor heterogeneity of driver mutations in TP53-driven non-small cell lung cancer","volume":"140","author":"Zhang","year":"2017","journal-title":"Int J Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12943-019-0939-9","article-title":"Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing","volume":"18","author":"Zhang","year":"2019","journal-title":"Mol Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e010249","DOI":"10.1136\/jitc-2024-010249","article-title":"Neoantigen architectures define immunogenicity and drive immune evasion of tumors with heterogenous neoantigen expression","volume":"12","author":"Roerden","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00336-2","article-title":"Genetic and non-genetic clonal diversity in cancer evolution","volume":"21","author":"Black","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12943-021-01331-9","article-title":"Intratumoral heterogeneity as a predictive biomarker in anti-PD-(L)1 therapies for non-small cell lung cancer","volume":"20","author":"Fang","year":"2021","journal-title":"Mol Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.744064","article-title":"Intratumor heterogeneity as a prognostic factor in solid tumors: a systematic review and meta-analysis","volume":"11","author":"Yu","year":"2021","journal-title":"Front Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2022.100028","article-title":"Analysis of immune intratumor heterogeneity highlights immunoregulatory and coinhibitory lymphocytes as hallmarks of recurrence in stage I non-small cell lung cancer","volume":"36","author":"Francisco-Cruz","year":"2023","journal-title":"Mod Pathol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.ccell.2018.03.018","article-title":"Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer","volume":"33","author":"Hellmann","year":"2018","journal-title":"Cancer Cell"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24043988","article-title":"Genomic and glycolytic entropy are reliable radiogenomic heterogeneity biomarkers for non-small cell lung cancer","volume":"24","author":"Chen","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B14","doi-asserted-by":"publisher","first-page":"812","DOI":"10.25205\/978-5-4437-1526-1-363","article-title":"The immune landscape of cancer","volume":"48","author":"The Cancer Genome Atlas Research","year":"2018","journal-title":"Immunity"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2014.06.005","article-title":"Tumour heterogeneity and the evolution of polyclonal drug resistance","volume":"8","author":"Burrell","year":"2014","journal-title":"Mol Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1158\/1078-0432.ccr-21-1355","article-title":"Intratumor heterogeneity and antitumor immunity shape one another bidirectionally","volume":"28","author":"Wolf","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-24-226","article-title":"Differential impact of intratumor heterogeneity (ITH) on survival outcomes in early-stage lung squamous and adenocarcinoma based on tumor mutational burden (TMB)","volume":"13","author":"Fridland","year":"2024","journal-title":"Transl Lung Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00673","article-title":"Association between tumor mutation burden (TMB) and outcomes of cancer patients treated with PD-1\/PD-L1 inhibitions: a meta-analysis","volume":"10","author":"Zhu","year":"2019","journal-title":"Front Pharmacol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00932-9","article-title":"Tumour mutational burden: clinical utility, challenges and emerging improvements","volume":"21","author":"Budczies","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-024-01111-8","article-title":"Cancer immune evasion, immunoediting and intratumour heterogeneity","volume":"25","author":"Roerden","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2024.107111","article-title":"Deciphering molecular relapse and intra-tumor heterogeneity in non-metastatic resectable head and neck squamous cell carcinoma using circulating tumor DNA","volume":"160","author":"Marret","year":"2025","journal-title":"Oral Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s12916-022-02444-8","article-title":"Increased blood-based intratumor heterogeneity (bITH) is associated with unfavorable outcomes of immune checkpoint inhibitors plus chemotherapy in non-small cell lung cancer","volume":"20","author":"Zhou","year":"2022","journal-title":"BMC Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.7","article-title":"Liquid biopsies come of age: towards implementation of circulating tumour DNA","volume":"17","author":"Wan","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202402716","article-title":"Spatial transcriptome-wide profiling of small cell lung cancer reveals intra-tumoral molecular and subtype heterogeneity","volume":"11","author":"Zhang","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ads8323","article-title":"Noninvasive prognostic classification of ITH in HCC with multi-omics insights and therapeutic implications","volume":"11","author":"Xie","year":"2025","journal-title":"Sci Adv"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adf0837","article-title":"Radiogenomic-based multiomic analysis reveals imaging intratumor heterogeneity phenotypes and therapeutic targets","volume":"9","author":"Su","year":"2023","journal-title":"Sci Adv"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-05783-5","article-title":"The evolution of lung cancer and impact of subclonal selection in TRACERx","volume":"616","author":"Frankell","year":"2023","journal-title":"Nature"},{"key":"B28","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1186\/s12935-025-03944-2","article-title":"Integration of multi-omics approaches in exploring intra-tumoral heterogeneity","volume":"25","author":"Dong","year":"2025","journal-title":"Cancer Cell Int"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"B30","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.semcancer.2021.02.013","article-title":"Impact of cancer evolution on immune surveillance and checkpoint inhibitor response","volume":"84","author":"Wu","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.02.006","article-title":"High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types","volume":"32","author":"McGrail","year":"2021","journal-title":"Ann Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2022.40.16_suppl.2617","article-title":"XIRP2 mutation as an indicator stratified patients benefit from immune checkpoint inhibitors in NSCLC","volume":"40","author":"Chen","year":"2022","journal-title":"J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-021-00612-z","article-title":"Epigenetic dysregulation of immune-related pathways in cancer: bioinformatics tools and visualization","volume":"53","author":"Berglund","year":"2021","journal-title":"Exp Mol Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.924781","article-title":"Differential infiltration of immune cells driven by tumor heterogeneity reveals two immune subtypes in lung adenocarcinoma","volume":"13","author":"Wang","year":"2022","journal-title":"Front Genet"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1852284\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T05:34:50Z","timestamp":1786426490000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1852284\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":34,"alternative-id":["10.3389\/fimmu.2026.1852284"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1852284","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"article-number":"1852284"}}